It is made available under a CC-BY-NC-ND 4.0 International license .

Heterogenous Cellular and Humoral Immune Trajectories after SARS-CoV-2 Infection: Compensatory Responses in a Population-Based Cohort

3

- 4 **Authors:** Dominik Menges¹[†], Kyra D. Zens^{1,2}[†], Tala Ballouz¹[†], Nicole Caduff^{1,2}, Daniel
- 5 Llanas-Cornejo¹, Hélène E. Aschmann^{1,3}, Anja Domenghino^{1,4}, Céline Pellaton⁵, Matthieu

6 Perreau⁵, Craig Fenwick⁵, Giuseppe Pantaleo⁵, Christian R. Kahlert^{6,7}, Christian Münz², Milo A.

7 Puhan^{1*}, Jan S. Fehr¹

8 Affiliations:

- ⁹ ¹Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich (UZH),
- 10 Zurich, Switzerland.
- ¹¹ ² Institute for Experimental Immunology, University of Zurich (UZH), Zurich, Switzerland.
- ³ Department of Epidemiology, University of California San Francisco, San Francisco, USA.
- ⁴ Department of Visceral and Transplantation Surgery, University Hospital Zurich (USZ),
- 14 University of Zurich (UZH), Zurich, Switzerland.
- ⁵ Service of Immunology and Allergy, Lausanne University Hospital (CHUV), University of
- 16 Lausanne (UNIL), Lausanne, Switzerland
- ⁶ Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital St. Gallen, St.
- 18 Gallen, Switzerland
- ⁷ Division of Infectious Diseases and Hospital Epidemiology, Children's Hospital of Eastern
- 20 Switzerland, St. Gallen, Switzerland
- 21
- 22 * Corresponding author. Email: miloalan.puhan@uzh.ch.
- 23 † These authors contributed equally to this work.
- 24
- 25

It is made available under a CC-BY-NC-ND 4.0 International license .

26 Abstract: To better understand the development of immunity against SARS-CoV-2 over time, 27 we evaluated humoral and cellular responses a population-based cohort of SARS-CoV-2-infected 28 individuals covering the full spectrum of COVID-19 up to 217 days after diagnosis. We 29 characterized anti-Spike (S)-IgA and -IgG antibody responses in 431 individuals and found that about 85% develop and maintain anti-S-IgG responses over time. In a subsample of 64 30 31 participants selected for a detailed characterization of immune responses, we additionally 32 evaluated anti-Nucleocapsid (N)-IgG antibodies and T cell responses specific to viral Membrane 33 (M), N, and S proteins. Most participants had detectable T cell responses to at least one of the 34 four peptide pools analyzed, which were more frequent than antibody seropositivity. We found a 35 moderate correlation between antibody and T cell responses, which declined over time and 36 suggests important variability in response patterns between individuals. The heterogeneity of 37 immune trajectories was further analyzed using cluster analyses taking into account joint 38 antibody and T cell responses over time. We identified five distinct immune trajectory patterns, 39 which were characterized by specific antibody, T cell and T cell subset patterns along with 40 disease severity and demographic factors. Higher age, male sex, higher disease severity and 41 being a non-smoker was significantly associated with stronger immune responses. Overall, the 42 results highlight that there is a consistent and maintained antibody response among most SARS-43 CoV-2-infected individuals, while T cell responses appear to be more heterogenous but 44 potentially compensatory among those with low antibody responses.

45

46 One Sentence Summary: Presence of heterogenous immune response trajectories after SARS47 CoV-2 infection with potential compensatory role of T cells among individuals with low
48 antibody responses.

It is made available under a CC-BY-NC-ND 4.0 International license .

49

50 Main Text:

51 **INTRODUCTION**

52	Almost two years after its start, the SARS-CoV-2 pandemic remains a threat to public
53	health worldwide and has resulted in hundreds of million cases and millions of deaths globally
54	(1). Control of the pandemic now relies largely on the development of robust immunity in the
55	population after infection, vaccination, or both, which necessitates an in-depth understanding of
56	humoral and cellular responses to the virus.
57	Several studies have characterized B and T cell-mediated immune responses against
58	SARS-CoV-2 and showed that both antibodies and T cells are generated in most people after
59	infection (2–19). Immunoglobulin (Ig) spike specific antibodies have been detected within a few
60	days after infection (4, 14–16, 19–22) and their neutralizing capacity has been confirmed (5, 12,
61	14, 18, 22–26), with the magnitude of response positively correlating with disease severity (7,
62	17, 21, 27-30). However, studies have also shown varying results regarding the longitudinal
63	changes of these antibody responses. While certain studies found that antibodies persist for
64	several months after infection (8, 10, 25, 26, 29, 31–37), some reported declining levels of
65	antibodies within a few months, particularly among those with mild disease (30, 38–42), raising
66	concerns about the longevity of protection against re-infection. On the other hand, T cell-
67	mediated immunity generally seems to be more stable. There is some evidence that robust T cell
68	responses are developed even after mildly symptomatic coronavirus disease 2019 (COVID-19)
69	or asymptomatic infection and despite low levels or a complete absence of antibodies (8–10, 28,
70	31, 43, 44). While these studies have significantly advanced the general understanding of
71	immunological responses after SARS-CoV-2 infection, most were conducted in highly specific

It is made available under a CC-BY-NC-ND 4.0 International license .

populations or using convenience samples. Few have longitudinally assessed the diverse components of the immune response within the same individuals (2, 8, 28, 31) and in cohorts representative of the entire range of the infected population (8, 28, 31). Furthermore, despite evidence of heterogeneous immune responses between individuals and the knowledge that antibodies and T cells act together at different stages of a viral infection to protect against severe disease and re-infection, little attention has been paid to capturing or describing the diverse joint trajectories of antibodies and T cells within individuals infected with SARS-CoV-2.

79 In this study, we analyzed longitudinal patterns of humoral and cellular immune 80 responses for up to six months post-diagnosis in a population-based cohort of SARS-CoV-2-81 infected individuals across the full COVID-19 disease spectrum. We first characterized anti-82 Spike (S) IgA and IgG antibody responses and estimated their decay rates up to 217 days post-83 diagnosis in 431 individuals. In a subsample of 64 participants selected to cover the full clinical 84 spectrum of SARS-CoV-2 infection and antibody responses, we performed a detailed evaluation 85 of anti-Nucleocapsid (N) IgG antibodies and T cell responses specific to viral Membrane (M), N, 86 or S proteins (including the S1 and the majority of the S2 domains). Based on the co-evolution of 87 both antibody and T cell responses over time, we defined five distinct immune trajectory patterns 88 post-infection. Overall, this longitudinal study highlights that there is a consistent antibody 89 response among most, but not all, SARS-CoV-2-infected individuals up to six months, while T 90 cell responses appear to be more heterogenous, but potentially compensatory among those with 91 low antibody responses.

92

93 **RESULTS**

94 Study population and sample measurements

It is made available under a CC-BY-NC-ND 4.0 International license .

95	In this analysis, we included measurements from 431 SARS-CoV-2-infected individuals,
96	selected as a random, age-stratified sample of all SARS-CoV-2-infected individuals reported to
97	the Department of Health of the Canton of Zurich between 06 August 2020 and 26 January 2021.
98	Peripheral blood samples were collected for immunological analysis at two weeks, one month,
99	three months, and six months after diagnosis of infection (Fig. 1A). The median age of
100	participants was 52 years (interquartile range (IQR) 35-68 years) and 212 (49%) were female
101	(Supplementary Table S1). Fifty-nine (14%) of the participants were smokers and 131 (30%) had
102	at least one comorbidity, most commonly hypertension (16%) and respiratory diseases (7%).
103	Most participants (83%) were symptomatic, with 163 (38%) reporting between one and five
104	symptoms and 192 (45%) reporting six symptoms or more during acute infection. Within two
105	weeks of diagnosis, 18 (4%) participants required hospitalization for reasons related to COVID-
106	19, among which two participants were admitted to an intensive care unit. At six months after
107	diagnosis, three participants (0.7%) reported a SARS-CoV-2 reinfection and 80 (19%) were
108	vaccinated with at least one dose (all with mRNA vaccines).
109	We selected a subsample of 64 individuals for a detailed characterization of immune
110	responses (i.e., additional anti-N antibody testing as well as ELISpot and flow cytometric
111	analyses of virus-specific T cells), aiming to cover the full spectrum of disease severity (i.e.,
112	asymptomatic to hospitalized), antibody responses (i.e., low to high anti-S-IgA and -IgG
113	antibody responses) and balanced in terms of age and sex (Fig. 1B). In this subsample, the
114	median age was 53.5 (IQR 33.5-68 years) and 56% of participants were female (Supplementary
115	Table S1). 69% of the participants had symptoms of COVID-19, with 27% reporting between
116	one and five symptoms and 42% reporting six or more symptoms. Eleven (17%) of the

medRxiv preprint doi: https://doi.org/10.1101/2021.12.15.21267776; this version posted December 16, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

participants were hospitalized due to COVID-19 and one participant required admission to anintensive care unit.

119	In summary, anti-S antibody responses were characterized in 431 SARS-CoV-2 infected
120	individuals at two weeks, one month, three months and six months after diagnosis. Anti-N
121	antibody responses, as well as M-, N-, S1 domain- and S2 domain-specific T cell responses were
122	additionally measured in a subsample of 64 individuals, covering the full clinical spectrum and
123	range of S-specific antibody responses at these timepoints.

124

Longitudinal follow-up of patients recovering from COVID-19 highlights sustained anti Spike IgG responses, anti-Nucleocapsid and anti-Spike Domain 2 T cell responses, and
 CD8⁺ T cell responses

128 Using a highly sensitive Luminex-based assay (45), we first assessed levels of SARS-129 CoV-2 S-specific IgA and IgG or N-specific IgG in blood plasma over time. Within the full 130 study population (n=431) we found that the median anti-S-IgA response was highest by two 131 weeks post-diagnosis, after which responses declined steadily up to six months (Fig. 2A, 132 Supplementary Tables S2 and S3). In contrast, anti-S-IgG responses peaked later at one month 133 post-diagnosis, persisted until three months, and then waned slightly until the six month follow-134 up (Fig. 2B). Among the subsample (n=64) we found that anti-N-IgG responses followed a 135 similar initial kinetic to that of anti-S-IgG (peaking at month one), but the decline over time was 136 more pronounced (Fig. 2C). From these data, we utilized a linear decay model adjusted for time 137 from diagnosis to maximum antibody concentration, to estimate the half-life of each antibody 138 subtype. From the full population we estimated the half-life of anti-S-IgA to be 71 days (95% CI

It is made available under a CC-BY-NC-ND 4.0 International license .

139	66–76 days, Fig. 2D) and 145 days (135–156 days; Fig. 2E) for anti-S-IgG. From the subsample,
140	we estimated the half-life of anti-N-IgG to be 86 days (76-99 days; Fig. 2F).

141 We further evaluated the level of seropositivity for each antibody subtype. In the full 142 study population, we found that 83% (79-86%) and 82% (78-86%) of individuals were anti-S-143 IgA or anti-S-IgG seropositive, respectively at two weeks post-diagnosis (Supplementary Fig. 144 S1A, Supplementary Table S2). While the percentage of anti-S-IgA-seropositive participants 145 decreased over time reaching 70% (65–75%) at six months, the percentage remaining anti-S-146 IgG-seropositive was more stable (81%, 77–85%). Overall, 85% of the population was positive 147 for either anti-S-IgA or -IgG at three (81–88%) and six (81–88%) months post-diagnosis. Of 148 note, only ten participants (2.3%) were initially seropositive (either anti-S-IgA or -IgG) but 149 became seronegative within six months. Estimates were similar in age group-weighted sensitivity 150 analyses (Supplementary Table S4). In the subsample, 59% of the participants were seropositive 151 each for anti-S-IgA and -IgG, and 54% were seropositive for anti-N-IgG at two weeks. At six 152 months, 61%, 66% and 41% were seropositive for anti-S-IgA, anti-S-IgG and anti-N-IgG, 153 respectively (Supplementary Fig. S1B, Supplementary Table S3). Taken together, these findings 154 suggest that S-specific IgG responses are more robust than S-specific IgA or N-specific IgG 155 responses following SARS-CoV-2 infection.

In the subsample, we additionally evaluated virus-specific T cell populations using an interferon-gamma ELISpot assay, assessing responses to overlapping peptide pools spanning the entire SARS-CoV-2 M and N proteins, the S1 domain of the S protein (which contains the Receptor Binding Domain (RBD)), or a mix of other predicted immunodominant epitopes within the S protein, containing the majority of the S2 domain (which we refer to here as S2 for simplicity). We found that 84% (72–91%) of individuals had detectable T cell responses to at

It is made available under a CC-BY-NC-ND 4.0 International license .

162	least one of the four tested peptide pools at two weeks post-infection, dropping to 71% (58-81%)
163	at six months (Fig. 3A, Supplementary Fig. S1C). Positivity to individual peptide pools ranged
164	from 71% (59–82%; S2) to 80% (68–89%; M) at two weeks to 46% (33–59%; S1) to 51% (38–
165	64%; N) at six months, with no discernible differences in positivity between pools at any
166	timepoint (Fig. 3A, Supplementary Fig. S1C, Supplementary Table S3). Assessing the combined
167	T cell response to all four peptide pools over time, M-specific T cells made up 33% of the total
168	detectable T cell response at two weeks of follow-up, compared to 29% S1-specific, 21% N-
169	specific, and 16% S2-specific T cells (Fig. 3B). Proportions remained stable up to six months,
170	contributing 26%, 26%, 27% and 21% to the total T cell response, respectively. Similar to
171	antibody responses, we estimated decay kinetics for individual peptide pool-specific T cell
172	responses or for the overall T cell response by summing the responses to individual peptide
173	pools. For the overall T cell response, we estimated a half-life of 145 (80-781) days
174	(Supplementary Fig. S1D). For individual peptide pools, we estimated the half-life of M and S1-
175	specific T cells to be substantially shorter (128 days and 126 days, respectively) compared to that
176	of N and S2-specific T cells (227 days and 266 days, respectively), suggesting that the latter may
177	provide more durable responses following infection (Supplementary Fig. S1E to S1H).
178	We further evaluated SARS-CoV-2-specific CD4 ⁺ and CD8 ⁺ T cells in the subsample
179	using a Flow Cytometry-based Activation-Induced Marker (AIM) assay. Using the markers
180	CD137 (4-1BB) and CD134 (OX-40) for CD4 ⁺ T cells or CD69 and CD137 for CD8 ⁺ T cells, we
181	determined frequencies of activated cells following in vitro stimulation with a combined pool of
182	M, N, S1, and S2 peptides (Fig. 3C). We found similar frequencies of total peripheral blood
183	AIM ⁺ CD4 ⁺ or AIM ⁺ CD8 ⁺ T cells (approximately 0.2–0.3%) at two weeks post-diagnosis. For
184	CD4 ⁺ T cells, this declined over time to 0.1% at six months, although this did not reach statistical

It is made available under a CC-BY-NC-ND 4.0 International license .

185	significance (p=0.11, Kruskal-Wallis test; Fig. 3D). In contrast, for CD8 ⁺ T cells, frequencies of
186	AIM^+ cells were more stable over time, remaining at 0.2% up to six months post-infection. In
187	assessing the phenotype of AIM ⁺ T cells in the blood, CD4 ⁺ AIM ⁺ T cells were predominantly
188	central memory T cells (TCM), while CD8 ⁺ AIM ⁺ T cells were predominantly T effector memory
189	cells re-expressing CD45RA (TEMRA; Fig. 3E). Taken together, our results suggest that, CD8 ⁺
190	T cells, in addition to anti-S IgG, and M- and S-specific T cells, act as more long-lasting
191	components of SARS-CoV-2-specific immunity following infection.

192

193 Sustained, strong concordance within antibody or T cell responses, but moderate

194 concordance between antibody and T cell responses which declines over time

195 To better understand the relationship within and between antibody and T cell responses 196 over time, we next used the subsample to evaluate concordance by comparing the levels of 197 antibody and T cell responses. Within the overall antibody response (anti-S-IgA, -S-IgG, -N-198 IgG), we observed a strong, positive correlation in the magnitude of response among different 199 subtypes at each timepoint post-diagnosis (Fig. 4A). Similarly, within the overall T cell response, 200 we observed a strong, positive correlation in the magnitude of response among different peptide 201 pools at each timepoint (Fig. 4A). In comparing between antibody and T cell responses, 202 however, the correlation was less robust, but still present. At two weeks post-diagnosis, we 203 observed a weak to moderate, positive correlation between the magnitude of each antibody 204 subtype evaluated and overall (pooled M, N, S1, S2) T cell responses (anti-S-IgA Spearman 205 r=0.38; anti-S-IgG Spearman r=0.37; anti-N-IgG Spearman r=0.47; Fig. 4A). This correlation 206 decreased over time and was weak or no longer observed by six months of follow-up (anti-S-IgA 207 Spearman r=0.16; anti-S-IgG Spearman r=0.25; anti-N-IgG Spearman r=0.24). These findings

medRxiv preprint doi: https://doi.org/10.1101/2021.12.15.21267776; this version posted December 16, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

highlight that antibody and T cell responses tend to behave similarly (in terms of magnitude)
early in the immune response, but not necessarily in the longer term. Furthermore, the magnitude
of the response by one antibody subtype is better predicted by the response to other antibody
subtypes than by T cell responses, and vice versa.

212 We also assessed the proportion of individuals that were "positive" or "negative" for 213 antibody and T cell responses at each timepoint, comparing anti-S-IgA, anti-S-IgG, or anti-N-214 IgG to pooled T cells responses (positive to any peptide pool; Fig. 4B), or to specific peptide 215 pools (Supplementary Fig. S2A). At two weeks post-diagnosis, approximately 55-60% of 216 individuals were both antibody "positive" and pooled-T cell "positive", while approximately 10-217 15% were both antibody "negative" and pooled-T cell "negative" (Fig. 4B). Thus, overall 218 percent concordance between antibody responses and pooled T cell responses was approximately 219 70%, which was similar for anti-S-IgA, anti-S-IgG, and anti-N-IgG. By six months, concordance 220 between pooled T cell responses dropped to 55–60% (depending on antibody subtype). For both 221 anti-S-IgA and anti-S-IgG, this appeared to be primarily due to an increased fraction of 222 participants becoming T cell "negative". For anti-N-IgG, this drop appeared to be additionally 223 driven by an increasing fraction of anti-N-IgG "negative" participants. Patterns of antibody 224 subtype and T cell concordance were also similar between T cells specific to individual peptide 225 pools (M, N, S1, S2), and analogous trends were observed when evaluating test agreement using 226 Cohen's Kappa (Supplementary Fig. S2A and S2B). Together, these findings suggest that SARS-227 CoV-2-specific antibody and T cell responses correlate early after infection, but that this 228 correlation decreases with increasing time after infection.

229

230 Clustering of antibody and T cell responses reveals five distinct joint immune trajectories

It is made available under a CC-BY-NC-ND 4.0 International license .

231 We subsequently explored whether distinct patterns of joint antibody and T cell response 232 trajectories could be observed using a non-parametric longitudinal clustering algorithm (46, 47). 233 We identified five distinct joint trajectories of antibody subtypes and peptide pool-specific T cell 234 responses within the subsample (Fig. 5A and 5B). Clusters of participants were primarily defined 235 by the presence (clusters 1-4) or absence (cluster 5) of antibody responses, as well as distinct T 236 cell trajectories. When present, antibody trajectories generally followed the decay patterns 237 observed in the overall study population, characterized by waning anti-S-IgA and anti-N-IgG as 238 well as persistent anti-S-IgG. Meanwhile, T cell trajectories between clusters were more 239 heterogenous. We additionally examined T cell subsets using data from flow cytometric 240 analyses, which did not influence clustering, to identify differences in immune phenotypes 241 between clusters.

242 The *first cluster* (14% of subsample participants) was characterized by high antibody and 243 T cell responses, which remained high across all evaluated timepoints. T cell response 244 trajectories were similar for M, N, S1, S2 peptide pools, peaking at three months with a 245 subsequent slight decline up to six months post-diagnosis. N- and S2-specific T cell responses 246 were the most robust; at six months post-diagnosis, 88% participants had detectable N-specific T 247 cells and 75% had S2-specific T cells (Fig. 5C, Supplementary Fig. S3A). By flow cytomatric 248 analysis, individuals in cluster 1 had the highest total CD4⁺ T cell count at one and three months 249 post-diagnosis, but showing a decline at six months (Supplementary Fig. S3B). Additionally, 250 total CD8⁺ T cell numbers were lower compared to clusters 3-5 and showed a decline from three 251 to six months. We further found that individuals in this cluster had higher frequencies of both 252 CD4⁺AIM⁺ and CD8⁺AIM⁺ virus-specific T cells at all timepoints compared to all other clusters 253 except cluster 2 (Fig. 5C). We noted that participants belonging to the first cluster were mostly

It is made available under a CC-BY-NC-ND 4.0 International license .

254	older than 65 years (89%), male (56%) and 22% were smokers (Fig. 5D). The majority (78%)
255	had more than six COVID-19 symptoms and 44% were hospitalized within two weeks of
256	diagnosis, indicating more severe disease. Thus, cluster 1 tended to represent older individuals
257	with more severe disease and also robust antibody and cell-mediated immune responses.
258	The second cluster (12% of the subsample) was characterized by persistently high anti-S-
259	IgA and -IgG responses in all participants, who also demonstrated a steep increase in virus-
260	specific T cells from two weeks to one month post-diagnosis. T cell positivity subsequently
261	declined until six months post-diagnosis, with N- and S2-specific T cells being present in 63%
262	and 13% of participants, respectively (Fig. 5C, Supplementary Fig. S3A). By flow cytometry, we
263	found that individuals in this cluster had lower total CD8 ⁺ T cell numbers than those in all other
264	clusters at two weeks and one months, increasing up to three months post-diagnosis
265	(Supplementary Fig. S3B). Meanwhile, they peaked in total CD4 ⁺ T cells at one month, which is
266	consistent with the increase in T cell responses observed by ELISpot analysis between two
267	weeks and one month after diagnosis (Fig. 5C, Supplementary Fig. S3B). As in cluster 1,
268	frequencies of CD4 ⁺ AIM ⁺ and CD8 ⁺ AIM ⁺ T cells tended to be higher compared to other clusters
269	(Fig. 5C, Supplementary Fig. S3A). Also similar to cluster 1, most (63%) participants had six or
270	more symptoms and 25% were hospitalized (Fig. 5D). However, participants in this cluster were
271	mostly younger than 65 years (63%), female (63%) and non-smokers or ex-smokers (75%).
272	Thus, cluster 2 was composed mostly of younger females with more severe disease, but robust
273	antibody responses and T cell responses which may tend towards higher CD4 ⁺ responses.
274	The third cluster (19% of the subsample) was characterized by antibody responses which
275	were initially high, but declined more sharply than in clusters 1-2. Anti-S-IgG, however,
276	remained detectable in all participants up to the six month follow-up visit. Meanwhile, overall T

It is made available under a CC-BY-NC-ND 4.0 International license .

277 cell responses initially waned up to three months post-diagnosis, but then increased again for all 278 peptide pools by month six, at which point 92% of participants had detectable N-specific and S2-279 specific T cells (Fig. 5C, Supplementary Fig. S3A). By flow cytometry, individuals in this 280 cluster tended to have the highest CD8⁺ T cell numbers at two weeks compared to other clusters 281 (Supplementary Fig. S3B). Meanwhile, they showed a decline in CD4⁺ and CD8⁺ T cells and 282 natural killer (NK) cells at one month with a subsequent increase up to six months, which is 283 consistent with the increased T cell responses observed by ELISpot between the three month and 284 six month follow-ups (Fig. 5C). In addition, participants had higher CD19⁺CD27⁺ memory B 285 cells at three and six months compared to the other clusters (Supplementary Fig. S3B). The 286 characteristics of the participants in this cluster were similar to those in the second cluster, but 287 with only 8% requiring hospitalization during acute infection (Fig. 5D). Five of the participants 288 in this cluster had another PCR-test between three and six months after their infection, none of 289 which was positive. Together, cluster 3 appears to represent individuals with more mild disease 290 and more moderate, less-well-sustained antibody responses. The increase in T cell responses 291 between months three and six in these individuals may possibly represent a re-exposure event.

292 The *fourth cluster* (16% of the subsample) was characterized by the presence of 293 antibodies and a rapid decline of T cells specific to all peptide pools between the two week and 294 one month follow-up visits. By six months post-diagnosis, only 10% had detectable N-specific T 295 cells and none had S2-specific T cells (Fig. 5C, Supplementary Fig. S3A). By flow cytometry, 296 individuals in this cluster had higher total CD4⁺ T cell numbers compared to clusters 2 and 3, but 297 lower compared to clusters 1 and 5 at two weeks and one month, subsequently showing a decline 298 in total CD4⁺ and CD8⁺ T cells up to six months post-diagnosis (Supplementary Fig. S3B). This 299 cluster was characterized by participants who were predominantly male (80%), younger than 65

medRxiv preprint doi: https://doi.org/10.1101/2021.12.15.21267776; this version posted December 16, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

years (70%), and non- or ex-smokers (100%; Fig. 5D). About 40% reported having six
symptoms or more and 40% were hospitalized in the acute phase. Together, cluster 4 appears to
be comprised of young males with moderate to severe disease, but who also have less-wellsustained antibody and T cell responses.

304 The *fifth cluster* (39% of the subsample) was characterized by persistently low and 305 primarily negative antibody responses and variable T cell responses. About half of the 306 participants had detectable M- and N-specific T cells across all assessments. An increase in S1-307 and S2-specific T cells by three months was noted which was followed by a decline (Fig. 5C, 308 Supplementary Fig. S3A). Despite T cells responses which tended to be lower than for other 309 clusters by ELISpot, these individuals had higher total CD8⁺ T cell numbers compared to all 310 other clusters from one to six months post-diagnosis, as determined by flow cytometric analysis 311 (Supplementary Fig. S3B). They also had high total CD4⁺ T cell numbers compared to other 312 clusters (though not as high as cluster 1 at two weeks to three months), and showed a steady 313 increase in CD4⁺ and CD8⁺ T cells as well as NK cells up to six months (Supplementary Fig. 314 S3B). Most individuals within this cluster were younger than 65 years (80%), female (68%), and 315 had mild disease as reflected by the low reported symptom count with none of the individuals 316 requiring hospitalization (Fig. 5D). That individuals in cluster 5 experience relatively mild disease in the absence of substantial antibody responses suggests compensatory protection by 317 318 cell-mediated immune responses, possibly including T cells specific to viral proteins not 319 captured by the assays used in this study.

Overall, our findings demonstrate the presence of different joint trajectories of antibody
 and T cell immune responses after SARS-CoV-2 infection, highlighting the large heterogeneity

It is made available under a CC-BY-NC-ND 4.0 International license .

322 between individuals. We found that within these clusters, individuals shared similar patterns of 323

324

325 Demographic and clinical factors are associated with humoral and cellular immune

immune phenotypes as well as demographic and clinical characteristics.

326 responses

327 We then evaluated whether the demographic and clinical factors described within the 328 clusters were associated with antibody responses in the overall study population using adjusted 329 mixed-effects linear regression analyses. Consistent with other reports (7, 17, 21, 27–30, 48), we 330 found that older age (≥ 65 years) (p<0.001), male sex (p=0.011), higher symptom severity 331 defined as having one to five (p<0.001) or more than six COVID-19 symptoms (p<0.001), as 332 well as hospitalization (p=0.006) were statistically significantly associated with higher anti-S-333 IgG MFI ratios over time (Fig. 6A, Supplementary Table S5). Conversely, being a current 334 smoker was associated with lower responses (p=0.010). Results for anti-S-IgA MFI ratios in the 335 overall population were comparable (Fig. 6B, Supplementary Table S5), and similar trends were 336 identified for anti-N-IgG MFI ratios within the subsample (Fig. 6C). For T cell responses, we 337 found that older age (\geq 65 years) (p<0.001) and having more than six symptoms (p<0.001) during 338 the acute infection were associated with higher T cell counts over time within the subsample 339 (Fig. 6D, Supplementary Table S6). Sensitivity analyses for antibody or T cell positivity at two 340 weeks and six months after diagnosis using logistic regression models showed comparable trends 341 (Supplementary Tables S7 and S8). Therefore, severity of disease, age and smoking status are 342 associated with the magnitude of immune responses.

It is made available under a CC-BY-NC-ND 4.0 International license .

344 **DISCUSSION**

345	Further understanding of the characteristics and trajectories of immune responses after
346	natural infection remains important even with the rollout of vaccines worldwide. Here, we
347	provide a longitudinal evaluation of humoral and cellular immune responses simultaneously,
348	from shortly after, and up to 217 days after, SARS-CoV-2 infection, in a group of individuals
349	infected between August 2020 and January 2021 and covering the full spectrum of clinical
350	manifestation and S-specific antibody responses.
351	
352	Distinct kinetics of antibody and T cell responses by subset and specificity
353	We demonstrate that approximately 85% of individuals infected with SARS-CoV-2
354	develop S-specific IgA and IgG antibody responses, and that nearly all of these individuals
355	maintain these responses for up to six months of follow-up. Compared to S-specific IgG,
356	however, the proportion of participants with detectable anti-S-IgA decreased markedly over time
357	(from 85% to 70% at six months). Consistent with this, we found the half-life of anti-S-IgA was
358	considerably shorter (71 days, with a range of 42 to 210 days reported by other studies (2, 8, 18))
359	compared to that of anti-S-IgG (145 days, with a range of 36 to 245 days reported by other
360	studies (2, 8, 11, 33, 49–52)). This difference, however, is perhaps not surprising as the half-lives
361	of IgA responses, in general, are shorter than those of IgG. Interestingly, we further found that
362	anti-N-IgG responses waned more rapidly than those specific to S, with an estimated half-life of
363	only 86 days. These findings are consistent with those from other studies demonstrating anti-S-
364	IgG responses to be important for sustained protection against SARS-CoV-2. Furthermore, they
365	indicate that both the target of the antibody response as well as the isotype itself appear to
366	influence the duration of humoral immune responses after infection.

It is made available under a CC-BY-NC-ND 4.0 International license .

367	In the subsample of individuals selected to cover the full spectrum of clinical disease and
368	S-specific antibody responses, we also found that the majority had detectable, IFN-gamma-
369	producing T cell responses to at least one of the four peptide pools analyzed in this study. Based
370	on this polyclonal T cell response, we estimate a half-life of 145 days, which is consistent with
371	the literature $(2, 8)$. Overall T cell positivity in the subsample (nearly 85%) was higher than for
372	overall antibody seropositivity (just over 60%), suggesting that T cell responses are likely able to
373	provide compensatory protection, even in the absence of antibodies. However, as only a limited
374	range of antibody and T cell responses were tested here, it could also be possible that antibody
375	responses to other viral proteins, or of other subtypes, are capable of providing this protection.
376	Furthermore, the T cell peptide pools for which individuals tested positive were
377	heterogenous. For example, at six months, 50% of individuals were positive for any individual
378	pool despite an overall T cell positivity of approximately 70%, which illustrates the polyclonal
379	nature of the anti-viral T cell response. While M and S1 appeared to be immunodominant in
380	terms of the magnitude of T cell responses, they also decayed more rapidly, with half-lives of
381	128 and 126 days, compared to N and S2-specific responses with half-lives of 227 and 266 days,
382	respectively. Compared to S1, the S2 domain of the full-length spike protein shares a higher
383	degree of amino acid identity with endemic coronaviruses (53). For example, HCoV-HKU1
384	shares an amino acid identity of 42% with SARS-CoV-2 at the S2 domain of the spike protein
385	compared to 31% at the S1 domain. Therefore, the longer half-life of S2-specific, compared to
386	S1-specific T cells, could potentially be due to intermittent exposure to endemic coronaviruses
387	with similar S2 peptide sequences, resulting in the appearance of a prolonged and more durable
388	T cell response. Overall, our findings suggest that M and S1 responses may initially be more

medRxiv preprint doi: https://doi.org/10.1101/2021.12.15.21267776; this version posted December 16, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

robust, at least in terms of an IFN-gamma-producing response, but that perhaps responses to Nand S2 may be more durable.

391 In evaluating virus-specific CD4⁺ and CD8⁺ T cells by AIM assay we found that 392 frequencies of AIM⁺CD4⁺ or CD8⁺ T cells were similar at two weeks post-infection, but that 393 activated, virus-specific CD4⁺ T cells tended to decline over the six months of follow-up, 394 whereas levels of activated, virus-specific CD8⁺ T cells remained more stable. Furthermore, 395 CD4⁺AIM⁺ T cells were predominantly of TCM phenotype, and this remained consistent 396 throughout the convalescent period, whereas CD8⁺AIM⁺T cells had a predominantly TEMRA 397 phenotype throughout this period consistent with previous studies (8, 54, 55). These findings 398 support the idea that CD4⁺ T cells may play an important role in maintaining the immune 399 response and immunological memory, whereas CD8⁺ T cells may play a more direct role in the 400 anti-viral immune response as highly activated and more terminally-differentiated cytotoxic

401 lymphocytes.

402

403 Concordance of Antibody and T Cell Responses and Immune Response Trajectories

We further evaluated the relationship between antibody and T cell responses within individuals over time, as well as the patterns of these responses within the population. We found a strong, positive correlation between the three antibody subtypes evaluated here. Similarly, T cell responses to M, N, S1, and S2 peptide pools also demonstrated a strong positive correlation, suggesting that, although there may be some variation between distinct subtypes or specificities, both overall antibody and T cell responses tended to behave similarly.

It is made available under a CC-BY-NC-ND 4.0 International license .

410 The relationship between antibody and T cell responses, however, was less strong. We 411 observed a weak to moderate positive correlation early after infection, where increased antibody 412 responses tended to predict increased T cell responses to some degree. Meanwhile, correlations 413 became weaker later during follow-up and were weak or no longer present by six months. In 414 assessing the concordance between antibody and T cell responses, we also found that, at two 415 weeks, more than 70% of participants had concordant results (58% both antibody and T cell 416 positive and 13% both antibody and T cell negative). After six months, this dropped to 55-60%. 417 These findings suggest that individuals had differing immune responses following infection 418 (possibly due to differences in viral load or primary site of infection or previous immune 419 history), and that they perhaps retain differing subsets of immune memory components which 420 could be recalled upon reinfection.

421 Based on this idea, we explored whether there are heterogeneous immune trajectories 422 which individuals tend to follow in response to infection, and which might influence not only 423 their response to infection, but also the immune memory populations which they establish. Using 424 a longitudinal clustering algorithm, we assessed different patterns of immune responses between 425 individuals over time. We identified five distinct joint trajectories of antibody and T cell 426 responses. These trajectories were primarily based on the presence or absence of antibodies and 427 varying T cell responses. Interestingly, we observed distinct clinical characteristics between 428 these clusters. We found that clusters with the most robust immune responses, i.e., clusters 1 and 429 2, included older participants who had more severe COVID-19 as reflected by hospitalization 430 and the number of reported symptoms. This finding is not surprising as older age and disease 431 severity have been consistently reported to be associated with higher immune responses to 432 SARS-CoV-2 (7, 17, 21, 27–30), and other studies primarily conducted in patients with severe

It is made available under a CC-BY-NC-ND 4.0 International license .

433 COVID-19 or requiring hospitalization observed similar patterns (4, 16, 21). These findings were 434 confirmed in association analyses in the overall study population, in which we found that older 435 age, male sex, and higher disease severity were strongly associated with stronger immune 436 responses. In contrast, clusters 4 and 5 appeared to have less robust antibody and T cell 437 responses. Cluster 5, in which participants were distinctly antibody negative, consisted mainly of 438 younger females who reported mild COVID-19 or asymptomatic infection. Some T cell 439 responses were present in half of these participants which, in conjunction with the generally less 440 severe presentation, may point towards compensatory mechanisms of T cell populations in 441 protecting from more severe COVID-19. Remarkably, in cluster 3, we noted a considerable 442 increase in virus-specific T cells, and, to a lesser extent, in anti-S-IgA, after an initial decline up 443 to three months after infection. In combination with the increase in N-specific T cells, this may 444 indicate a possible re-exposure to the virus. Of note, about half of cluster participants underwent 445 SARS-CoV-2 testing between three and six months, which may be indicative of potential 446 exposure events or symptomatic episodes. None, however, tested positive. This again highlights 447 the role of the immune system in protecting from severe disease upon re-exposure, as 448 reinfections may present with milder disease than the primary infection or may even be 449 asymptomatic. Furthermore, this finding demonstrates that reinfections might be more frequent 450 than reported, since many would remain undetected.

451

452 Limitations

Our cohort is one of few population-based and longitudinal studies assessing various
components of the immune system in a sample of patients that is representative of the full
spectrum of COVID-19. However, some limitations should be considered when interpreting our

It is made available under a CC-BY-NC-ND 4.0 International license .

456 findings. We used single assays to measure antibodies or T cells in our study. The accuracy and 457 detection levels may differ between tests and thus individuals who are negative in one assay may 458 not be so in another. Nevertheless, the Luminex assay that we used for antibody detection has 459 been extensively validated and was shown to be highly sensitive and specific (45). Second, we 460 did not measure the neutralizing capacity of antibody responses. However, other studies have 461 shown that neutralizing capacity correlates strongly with measured levels of binding antibodies 462 (3, 25, 56). Third, we limited our T cell analysis to the three dominant antigens for cellular 463 immune responses (S, M and N) (2, 8, 57). However, we cannot exclude that in some of the 464 participants, subdominant T cell responses against other viral antigens play important roles, 465 which may have led to an underestimation of the proportion of individuals with T cell responses. 466 Fourth, the cluster analysis bears the limitations that are inherent to the methodology. Using a 467 clustering algorithm that separates the study population into distinct clusters may not be 468 necessarily reflective of clinically meaningful differences. However, we identified distinct 469 clinical and immunological correlates within the different clusters, including various factors 470 (such as the data from flow cytometry) that were not used within the clustering model. 471 Therefore, we consider our results to be relatively robust and leading to a meaningful description 472 of different immune trajectories. Finally, we analyzed antibody and T cell testing results only up to six months, limiting our findings regarding the durability of immune responses. Furthermore, 473 474 the limited sample size was a pragmatic choice to ensure feasibility of the project, and further 475 immune response patterns may have been observable with additional data. Nonetheless, we 476 believe our study provides a valuable and unique in-depth analysis of joint humoral and cellular 477 immune response trajectories which may lead to further insights on the variability of immune 478 responses to SARS-CoV-2.

It is made available under a CC-BY-NC-ND 4.0 International license .

479

480 Conclusion

481	In conclusion, our analyses provide important insights into the different dynamics of
482	antibody and T cell immune responses in individuals covering the entire range from
483	asymptomatic to severe courses of COVID-19. Based on the observed humoral and cellular
484	immune responses, we identify variable immunological trajectories and categorize these into five
485	distinct clusters. While antibody and T cell responses strongly correlate in some individuals,
486	their discordance in other individuals may point towards more complex interactions of the
487	immune system among infected individuals. Overall, our findings indicate that virus-specific T
488	cell responses may be compensatory in the absence of humoral immunity against SARS-CoV-2.
489	
490	MATERIALS AND METHODS
491	Study Design and Participants
492	We recruited a population-based, age-stratified, random sample of 431 individuals
493	diagnosed with SARS-CoV-2 infection between 6 August 2020 and 19 January 2021 in the
494	Canton of Zurich, Switzerland. Study participants were identified through the Department of
495	Health of the Canton of Zurich, which records all diagnosed SARS-CoV-2 cases within the
496	Canton through mandatory case reporting. Eligibility criteria were having a polymerase chain
497	reaction (PCR)-confirmed SARS-CoV-2 diagnosis, being aged 18 years or older, residing in the
498	Canton of Zurich, understanding the German language, and being cognitively able to follow the
499	study procedures. We obtained written informed consent from all participants upon study

It is made available under a CC-BY-NC-ND 4.0 International license .

500 enrollment. The study protocol was approved by the Cantonal Ethics Committee of Zurich 501 (BASEC Registration No. 2020-01739) and prospectively registered (ISRCTN 14990068) (58). 502 We collected peripheral venous blood samples during study visits at two weeks, one 503 month, three months and six months post-diagnosis. Participants additionally provided 504 information regarding acute COVID-19 disease course, severity and symptoms, longer-term 505 health and complications, past medical history, and socio-demographics at the corresponding 506 timepoints through electronic questionnaires. 507 We selected 64 out of the 431 participants for a detailed characterization of immune 508 responses. This sample was aimed to be representative of the full spectrum of SARS-CoV-2 509 infection and associated immune responses. Participants in this subsample were selected at 510 random within strata based on clinical characteristics (asymptomatic disease, low and high 511 symptom count, hospitalization) and antibody responses up to one month (negative or low anti-512 S-IgA or -IgG response, positive or high anti-S-IgA or -IgG response), while ensuring balance 513 across sex and age groups. Based on preliminary assessments and evidence from other studies, 514 we deemed this sample size to be a sensible and pragmatic choice allowing to identify the range 515 and distinct trajectories of immune responses in infected individuals, while ensuring the 516 feasibility of the project.

517

518 Isolation of Plasma and PBMCs

519 K2 EDTA blood samples collected from participants at each study timepoint were 520 subjected to initial centrifugation to collect plasma, followed by isolation of PBMCs from the 521 remaining cellular fraction by density-gradient centrifugation using Ficoll–Paque (density

It is made available under a CC-BY-NC-ND 4.0 International license .

522 1.077g/ml). Plasma aliquots were stored at -20°C prior to IgA and IgG antibody titer analyses.

523 PBMCs were initially frozen at -80°C and transferred to liquid nitrogen prior to use in ELISpot

and Activation Induced Marker (AIM) Flow Cytometry assays.

525

526 Analysis of Spike-Specific IgA and IgG and Nucleocapsid-Specific IgG

527 Frozen plasma samples were thawed and analyzed for levels of Spike (S)-specific IgA 528 and IgG, or Nucleocapsid (N)-specific IgG by Luminex assay as described elsewhere (45). In 529 brief, assay beads were prepared by covalent coupling of either the SARS-CoV-2 Spike protein 530 trimer, or N-protein, with MagPlex beads using a Bio-Plex 356 Amine Coupling Kit (Bio-Rad) 531 per manufacturer's protocol. Protein-coupled beads were diluted and added to each well of Bio-532 Plex Pro 96-well Flat Bottom Plates (Bio-Rad). Beads were washed with PBS on a magnetic 533 plate washer (MAG2x program) and 50ul of individual serum samples diluted 1:300 in PBS were 534 added to plate wells. A pool of pre-Covid-19 pandemic healthy human sera was used as a 535 negative control (BioWest human serum AB males; VWR). Plates were incubated for 1 hour at 536 room temperature with shaking, washed with PBS and incubated with 50ul of a 1:100 dilution of 537 anti-human IgA-PE (for anti-IgA assay) or IgG-PE (for anti-IgG assay) secondary antibody 538 (OneLambda ThermoFisher) at room temperature for an additional 45 minutes with shaking. 539 After incubation, samples were washed with PBS and resuspended in reading buffer and read on 540 a Luminex FLEXMAP 3D plate reader (ThermoFisher) to obtain a Mean Fluorescence Intensity 541 (MFI) value for each sample. The MFI value for each serum sample was divided by the mean 542 value of the negative control samples to yield an MFI ratio. Based on negative control samples 543 and samples from PCR-positive donors, cut-off thresholds for MFI ratios used to determine 544 seropositivity were 6.5 for IgA and 6.0 for IgG. The lower limit of measured MFI ratios was

It is made available under a CC-BY-NC-ND 4.0 International license .

545	restricted to 1, representing equivalent fluorescence intensity compared to negative control
546	samples. For anti-S-IgG MFI ratios, an approximate conversion to BAU/ml is available based on
547	a cross-validation with the Roche Elecsys Anti-SARS-CoV-2 S immunoassay, for which a
548	reference table is provided (Supplementary Table S9).
549	
550	ELISpot Assay
551	T cell responses were assessed by ELISpot assay using the Human IFN-gamma ELISpot
552	Assay kit (R&D Systems) following the manufacturer's instructions. For the assay,
553	cryopreserved PBMCs were thawed and plated at 5e5 cells per well. Cells were stimulated 20h at
554	37°C with overlapping 15mer peptide pools spanning the entire M and N proteins or the S1
555	domain of the spike protein or a mix of the predicted immunodominant peptides from the spike
556	protein containing the majority of the S2 domain (M, N, S1 and S PepTivator peptide pools,
557	respectively; Miltenyi Biotec) at a concentration of lug/ml per individual peptide. As negative
558	controls, cells were incubated without peptide. As positive controls, 2.5e5 cells per well were
559	stimulated with anti-CD3 antibody (OKT3; Miltenyi Biotec). Spots were counted using an AID
560	iSpot Reader System with EliSpot 7.0 software (AID). Two times the number of spots in
561	unstimulated negative control wells were subtracted from the values of each test well and results
562	were normalized to the number of spots in anti-CD3 antibody-stimulated wells from the same
563	individual and timepoint and presented as spot-forming units (SFU) per 1e6 CD3+ cells. Results
564	were excluded if positive control wells were negative.

565

566 Flow Cytometry and Activation-Induced Marker (AIM) Assay

It is made available under a CC-BY-NC-ND 4.0 International license .

567	Cryopreserved PBMCs were thawed in RPMI-1640 (Gibco, Thermo Fisher Scientific)
568	supplemented with 5% human AB-serum (BioConcept) and 25U/ml benzonase (Sigma), and
569	plated in 96-UWell plates (Sarstedt) at a concentration of up to 1e6 cells per well in RPMI-1640
570	medium (Gibco, Thermo Fisher Scientific) supplemented with 10% human AB-serum
571	(BioConcept) and 1% Penicillin-Streptomycin (Thermo Fisher). SARS-CoV-2 PepTivator
572	peptide pools M, N, S1 and S (Miltenyi Biotec) were dissolved per manufacturer's instructions in
573	sterile water and combined into a single mega pool. PBMCs were cultured for 24h in a
574	humidified incubator at 37°C and 5% CO2 in the presence of either the SARS-CoV-2 mega pool
575	at 0.6nmol (appr. 1µg) of each peptide/ml, Phytohemagglutinin-L at 5µg/ml (Merck Millipore,
576	positive control) or culture medium (unstimulated condition). Peptide- and unstimulated samples
577	were run in duplicate whenever possible and longitudinal samples from individual participants
578	were included in the same assay. After 24 hours, cells were washed in staining buffer (PBS,
579	0.02% NaN ₃ , 2mM EDTA, 1% bovine serum albumin), blocked for 10 minutes with Human
580	TruStain FcX (Biolegend) on ice and stained for 30 minutes at 4°C with the following antibodies
581	in buffer supplemented with Super Bright Complete Staining Buffer (eBioscience): BUV395
582	anti-CD45RA (Clone: HI100, BD Bioscience, RRID:AB_2740037), BUV496 anti-CD8 (Clone:
583	RPA-T8, BD Bioscience, RRID:AB_2870223), BUV563 anti-CD56 (Clone: NCAM16.2, BD
584	Bioscience, RRID:AB_2870213), BUV661 anti-CD14 (Clone: M5E2, BD Bioscience,
585	RRID:AB_2871011), BUV737 anti-CD16 (Clone: 3G8, BD Bioscience, RRID:AB_2869578),
586	BUV805 anti-CD19 (Clone: SJ25C1, BD Bioscience, RRID:AB_2873553), BV421 anti-CD27
587	(Clone: O323, Biolegend, RRID:AB_11150782), BV510 anti-CD4 (Clone: OKt4, Biolegend,
588	RRID:AB_2561866), BV650 anti-CD38 (Clone: HB-7, Biolegend, RRID:AB_2566233), BV786
589	anti-CD3 (Clone: OKt3, Biolegend, RRID:AB_2563507), PE anti-IgD (Clone: IA6-2, Biolegend,

It is made available under a CC-BY-NC-ND 4.0 International license .

- 590 RRID:AB 10553900), PE/Dazzle594 anti-CCR7 (Clone: G043H7, Biolegend,
- 591 RRID:AB_2563641), FITC anti-HLA-DR (Clone: L243, Biolegend, RRID:AB_314682), PE-
- 592 Cy7 anti-CD137 (Clone: 4B4-1, Biolegend, RRID:AB_2207741), BB700 anti-CD134/OX40
- 593 (Clone: ACT35, BD Bioscience, RRID:AB 2743451), APC anti-CD69 (Clone: FN50,
- 594 Biolegend, RRID:AB 314845). Zombie NIR Fixable Viability Dye (Biolegend) was used to
- 595 exclude dead cells. After washing, samples were fixed with 1% PFA and acquired on Cytek
- 596 Aurora 5L spectral flow cytometer (Cytek). Data was analyzed using Cytek SpectroFlo (version
- 597 3.0.1) and FlowJo software (version 10, TreeStar Inc). Samples were excluded if the percentage
- 598 of live leukocytes was below 25%. SARS-CoV-2 antigen-specific T cells were measured as
- 599 AIM⁺ (CD134⁺CD137⁺) CD4⁺ T and (CD69⁺CD137⁺) CD8⁺ T cells. Unspecific activation in
- 600 unstimulated controls was subtracted and negative values were set to zero.
- 601

602 Statistical Analyses

603 We summarized population characteristics descriptively and report frequencies and 604 percentage or median and interquartile range, as applicable. We report age-stratified summary 605 statistics for the frequency of antibody and T cell responses and calculated 95% Wilson 606 confidence intervals to estimate the associated uncertainty. We excluded any data measured after 607 receipt of COVID-19 vaccination (first dose; n=2 participants at three months and n=78 608 participants at six months) or diagnosed reinfection (based on self-reported positive PCR or rapid 609 antigen test; n=3 participants at six months) from all analyses. All data were transformed using 610 natural logarithms for all comparative and associational analyses due to non-normal distributions 611 and ratio properties of the Ig MFI ratios (zero values being replaced by half of the lowest non-612 zero value). Results are visualized using a log10-transformation in figures.

It is made available under a CC-BY-NC-ND 4.0 International license .

613	To estimate antibody decay times, we first determined the maximum response timepoint
614	for each individual. We excluded data from individuals that were never tested positive for the
615	respective antibody (i.e., anti-S-IgA or -IgG, or anti-N-IgG). We then restricted the data to the
616	maximum and all subsequent timepoints and rescaled the time axis to start with the maximum
617	concentration, in order to restrict and align the data for the descending slope of antibody decay
618	(in line with previous studies (59, 60)). For T cells, we used the data as measured, as peak T cell
619	expansion typically occurs in the first week after infection (61) . We then fitted uni- and
620	multivariable mixed-effects linear decay models on the natural logarithm-transformed data using
621	random intercepts for individuals. We then calculated the half-life in days using the formula $\lambda =$
622	$ln(0.5) / \beta$, where β is the model-derived intercept (and associated uncertainty bounds). We
623	used mixed-model-based parametric bootstrap for the visualization of confidence bounds.
624	For assessing the correlation of antibody and T cell test results, we calculated Spearman
625	correlation coefficients for all combinations of antibody subtypes and epitope-specific T cells.
626	Furthermore, we assessed concordance by calculating the proportion of participants testing
627	positive or negative for antibody subtypes and overall T cells. And last, we further assessed
628	agreement by calculating unweighted Cohen's Kappa values for test positivity for all possible
629	combinations of antibody subtypes and virus-specific T cells.
630	We assessed the association between demographic and clinical factors and IgA and IgG
(21	MEL action on the size of the discount of the second of th

MFI ratios up to six months after diagnosis using uni- and multivariable mixed-effects linear
regression models. Model selection was based on prior knowledge and the Akaike and Bayesian
Information Criteria (AIC/BIC), with a difference of 2 points considered relevant. Age, sex, and
time since diagnosis were defined as a priori variables based on findings from previous studies.

It is made available under a CC-BY-NC-ND 4.0 International license .

We conducted sensitivity analyses for antibody positivity at two weeks and six months afterdiagnosis using uni- and multivariable logistic regression analyses.

637 To identify clusters of individuals with similar immune response trajectories over the four 638 assessment timepoints, we used the KmL3D k-means clustering method which allows the joint 639 evolution of multiple variables with repeated measures (46, 47). The algorithm requires 640 predefining the number of clusters. We chose four to six clusters based on a priori knowledge on 641 immune response patterns as well as exploratory analyses of the data. We specified 100 runs for 642 each k clusters (i.e., 300 times in total) and specified Euclidean distance with Gower adjustment 643 to estimate similarity between the trajectories. The selection of the final number of clusters was 644 based on maximizing the Calinski and Harabatz quality criterion (46, 47) as well as the expected 645 patterns in the data. Implementing the KmL3D algorithm requires that data for all variables 646 included in the analysis are available for all participants. Hence, missing data were imputed by 647 applying linear extrapolation with added variation ("Copy Mean" function (46, 47)). We plotted 648 the mean antibody and T cell responses for each cluster to explore differences in respective 649 immune response trajectories. Finally, we descriptively compared demographic and clinical 650 features of individuals in clusters to identify specific factors associated with each trajectory. 651 All analyses were performed using R (v4.1.1) (62), using the *Hmisc* (v4.5-0), *lme4* (v1.1-

652 27.1), *ImerTest* (v3.1-3) and *KmL3D* (v2.4.2) packages, and results were visualized using the
653 ggplot2 (v3.3.5), ggpubr (v0.4.0) and pheatmap (v1.0.12) packages.

654

655 Supplementary Materials

medRxiv preprint doi: https://doi.org/10.1101/2021.12.15.21267776; this version posted December 16, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

- 656 Fig. S1. Overall antibody and T cell positivity across timepoints and estimation of T cell decay
- 657 kinetics.
- Fig. S2. Concordance of antibody and T cell positivity over time.
- 659 Fig. S3. Antibody responses, cellular subsets and AIM+ T cells within clusters.
- 660 Table S1. Study population characteristics.
- Table S2. Anti-S-IgA and -IgG antibody responses in the overall study population over time.
- Table S3. Antibody and T cell responses in the subsample over time.
- Table S4. Sensitivity analysis regarding anti-S-IgA and -IgG antibody responses, weighted by
- age group.
- Table S5. Association between demographic and clinical factors and antibody responses overtime.
- 667 Table S6. Association between demographic and clinical factors and T cell responses over time.
- 668 Table S7. Association between demographic and clinical factors and anti-S-IgG antibody
- 669 positivity at two weeks and six months.
- Table S8. Association between demographic and clinical factors and overall T cell positivity at
- 671 two weeks and six months.
- Table S9. Reference table for converting anti-S-IgG MFI ratios to BAU/ml (based on Roche
- 673 Elecsys Anti-SARS-CoV-2 S immunoassay).

It is made available under a CC-BY-NC-ND 4.0 International license .

675 References and Notes

- 676 1. COVID Live Update: 259,111,945 Cases and 5,184,802 Deaths from the Coronavirus -
- 677 Worldometer, (available at https://www.worldometers.info/coronavirus/).
- 678 2. A. K. Wheatley, J. A. Juno, J. J. Wang, K. J. Selva, A. Reynaldi, H.-X. Tan, W. S. Lee, K.
- 679 M. Wragg, H. G. Kelly, R. Esterbauer, S. K. Davis, H. E. Kent, F. L. Mordant, T. E.
- 680 Schlub, D. L. Gordon, D. S. Khoury, K. Subbarao, D. Cromer, T. P. Gordon, A. W. Chung,
- 681 M. P. Davenport, S. J. Kent, Evolution of immune responses to SARS-CoV-2 in mild-
- 682 moderate COVID-19. *Nat Commun.* **12**, 1162 (2021).
- 683 3. W. N. Chia, F. Zhu, S. W. X. Ong, B. E. Young, S.-W. Fong, N. L. Bert, C. W. Tan, C. Tiu,
- J. Zhang, S. Y. Tan, S. Pada, Y.-H. Chan, C. Y. L. Tham, K. Kunasegaran, M. I.-C. Chen,
- 585 J. G. H. Low, Y.-S. Leo, L. Renia, A. Bertoletti, L. F. P. Ng, D. C. Lye, L.-F. Wang,
- 686 Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a

687 longitudinal study. *The Lancet Microbe*. **2**, e240–e249 (2021).

- 4. K. Li, B. Huang, M. Wu, A. Zhong, L. Li, Y. Cai, Z. Wang, L. Wu, M. Zhu, J. Li, Z. Wang,
- 689 W. Wu, W. Li, B. Bosco, Z. Gan, Q. Qiao, J. Wu, Q. Wang, S. Wang, X. Xia, Dynamic
- 690 changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from
- 691 COVID-19. *Nature Communications*. **11**, 6044 (2020).
- 5. K. Wang, Q.-X. Long, H.-J. Deng, J. Hu, Q.-Z. Gao, G.-J. Zhang, C.-L. He, L.-Y. Huang,
- 693 J.-L. Hu, J. Chen, N. Tang, A.-L. Huang, Longitudinal Dynamics of the Neutralizing
- 694 Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
- 695 Infection. *Clin Infect Dis.* **73**, e531–e539 (2021).

It is made available under a CC-BY-NC-ND 4.0 International license .

696	6.	K. KW. To, O. TY. Tsang, WS. Leung, A. R. Tam, TC. Wu, D. C. Lung, C. CY.
697		Yip, JP. Cai, J. MC. Chan, T. SH. Chik, D. PL. Lau, C. YC. Choi, LL. Chen, W
698		M. Chan, KH. Chan, J. D. Ip, A. CK. Ng, R. WS. Poon, CT. Luo, V. CC. Cheng, J.
699		FW. Chan, I. FN. Hung, Z. Chen, H. Chen, KY. Yuen, Temporal profiles of viral load
700		in posterior oropharyngeal saliva samples and serum antibody responses during infection by
701		SARS-CoV-2: an observational cohort study. The Lancet Infectious Diseases. 20, 565-574
702		(2020).
703	7.	K. L. Lynch, J. D. Whitman, N. P. Lacanienta, E. W. Beckerdite, S. A. Kastner, B. R. Shy,
704		G. M. Goldgof, A. G. Levine, S. P. Bapat, S. L. Stramer, J. H. Esensten, A. W. Hightower,
705		C. Bern, A. H. B. Wu, Magnitude and kinetics of anti-SARS-CoV-2 antibody responses and
706		their relationship to disease severity. Clin Infect Dis, ciaa979 (2020).
707	8.	J. M. Dan, J. Mateus, Y. Kato, K. M. Hastie, E. D. Yu, C. E. Faliti, A. Grifoni, S. I.
708		Ramirez, S. Haupt, A. Frazier, C. Nakao, V. Rayaprolu, S. A. Rawlings, B. Peters, F.
709		Krammer, V. Simon, E. O. Saphire, D. M. Smith, D. Weiskopf, A. Sette, S. Crotty,
710		Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.
711		Science. 371, eabf4063 (2021).
712	9.	A. Grifoni, D. Weiskopf, S. I. Ramirez, J. Mateus, J. M. Dan, C. R. Moderbacher, S. A.
713		Rawlings, A. Sutherland, L. Premkumar, R. S. Jadi, D. Marrama, A. M. de Silva, A.
714		Frazier, A. F. Carlin, J. A. Greenbaum, B. Peters, F. Krammer, D. M. Smith, S. Crotty, A.
715		Sette, Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-
716		19 Disease and Unexposed Individuals. Cell. 181, 1489-1501.e15 (2020).
717	10.	L. B. Rodda, J. Netland, L. Shehata, K. B. Pruner, P. A. Morawski, C. D. Thouvenel, K. K.
718		Takehara, J. Eggenberger, E. A. Hemann, H. R. Waterman, M. L. Fahning, Y. Chen, M.

It is made available under	a CC-BY-NC-ND) 4.0 International	license.
----------------------------	---------------	---------------------	----------

719		Hale, J. Rathe, C. Stokes, S. Wrenn, B. Fiala, L. Carter, J. A. Hamerman, N. P. King, M.
720		Gale, D. J. Campbell, D. J. Rawlings, M. Pepper, Functional SARS-CoV-2-Specific
721		Immune Memory Persists after Mild COVID-19. Cell. 184, 169-183.e17 (2021).
722	11.	D. S. Khoury, D. Cromer, A. Reynaldi, T. E. Schlub, A. K. Wheatley, J. A. Juno, K.
723		Subbarao, S. J. Kent, J. A. Triccas, M. P. Davenport, Neutralizing antibody levels are
724		highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat
725		Med. 27, 1205–1211 (2021).
726	12.	L. Ni, F. Ye, ML. Cheng, Y. Feng, YQ. Deng, H. Zhao, P. Wei, J. Ge, M. Gou, X. Li, L.
727		Sun, T. Cao, P. Wang, C. Zhou, R. Zhang, P. Liang, H. Guo, X. Wang, CF. Qin, F. Chen,
728		C. Dong, Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-
729		19 Convalescent Individuals. Immunity. 52, 971-977.e3 (2020).
730	13.	Y. Chen, A. Zuiani, S. Fischinger, J. Mullur, C. Atyeo, M. Travers, F. J. N. Lelis, K. M.
731		Pullen, H. Martin, P. Tong, A. Gautam, S. Habibi, J. Bensko, D. Gakpo, J. Feldman, B. M.
732		Hauser, T. M. Caradonna, Y. Cai, J. S. Burke, J. Lin, J. A. Lederer, E. C. Lam, C. L.
733		Lavine, M. S. Seaman, B. Chen, A. G. Schmidt, A. B. Balazs, D. A. Lauffenburger, G.
734		Alter, D. R. Wesemann, Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody
735		Production. Cell. 183, 1496-1507.e16 (2020).
736	14.	S. Fafi-Kremer, T. Bruel, Y. Madec, R. Grant, L. Tondeur, L. Grzelak, I. Staropoli, F.
737		Anna, P. Souque, S. Fernandes-Pellerin, N. Jolly, C. Renaudat, MN. Ungeheuer, C.
738		Schmidt-Mutter, N. Collongues, A. Bolle, A. Velay, N. Lefebvre, M. Mielcarek, N. Meyer,
739		D. Rey, P. Charneau, B. Hoen, J. D. Seze, O. Schwartz, A. Fontanet, Serologic responses to
740		SARS-CoV-2 infection among hospital staff with mild disease in eastern France.
741		EBioMedicine. 59 (2020), doi:10.1016/j.ebiom.2020.102915.

medRxiv preprint doi: https://doi.org/10.1101/2021.12.15.21267776; this version posted December 16, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

742	15.	QX. Long, E	3Z. Liu. H	J. Deng. G.	-C. Wu. K.	Deng, YK.	Chen, P. Liao	. JF. O	iu. Y.

- 743 Lin, X.-F. Cai, D.-Q. Wang, Y. Hu, J.-H. Ren, N. Tang, Y.-Y. Xu, L.-H. Yu, Z. Mo, F.
- 744 Gong, X.-L. Zhang, W.-G. Tian, L. Hu, X.-X. Zhang, J.-L. Xiang, H.-X. Du, H.-W. Liu, C.-
- 745 H. Lang, X.-H. Luo, S.-B. Wu, X.-P. Cui, Z. Zhou, M.-M. Zhu, J. Wang, C.-J. Xue, X.-F.
- 746 Li, L. Wang, Z.-J. Li, K. Wang, C.-C. Niu, Q.-J. Yang, X.-J. Tang, Y. Zhang, X.-M. Liu, J.-
- 747 J. Li, D.-C. Zhang, F. Zhang, P. Liu, J. Yuan, Q. Li, J.-L. Hu, J. Chen, A.-L. Huang,
- Antibody responses to SARS-CoV-2 in patients with COVID-19. *Nat Med.* 26, 845–848
- 749 (2020).
- 750 16. J. Zhao, Q. Yuan, H. Wang, W. Liu, X. Liao, Y. Su, X. Wang, J. Yuan, T. Li, J. Li, S. Qian,
- 751 C. Hong, F. Wang, Y. Liu, Z. Wang, Q. He, Z. Li, B. He, T. Zhang, Y. Fu, S. Ge, L. Liu, J.
- 752Zhang, N. Xia, Z. Zhang, Antibody Responses to SARS-CoV-2 in Patients With Novel
- 753 Coronavirus Disease 2019. *Clin Infect Dis.* **71**, 2027–2034 (2020).
- 17. D. F. Gudbjartsson, G. L. Norddahl, P. Melsted, K. Gunnarsdottir, H. Holm, E. Eythorsson,
- A. O. Arnthorsson, D. Helgason, K. Bjarnadottir, R. F. Ingvarsson, B. Thorsteinsdottir, S.
- 756 Kristjansdottir, K. Birgisdottir, A. M. Kristinsdottir, M. I. Sigurdsson, G. A. Arnadottir, E.
- 757 V. Ivarsdottir, M. Andresdottir, F. Jonsson, A. B. Agustsdottir, J. Berglund, B. Eiriksdottir,
- 758 R. Fridriksdottir, E. E. Gardarsdottir, M. Gottfredsson, O. S. Gretarsdottir, S.
- 759 Gudmundsdottir, K. R. Gudmundsson, T. R. Gunnarsdottir, A. Gylfason, A. Helgason, B.
- 760 O. Jensson, A. Jonasdottir, H. Jonsson, T. Kristjansson, K. G. Kristinsson, D. N.
- 761 Magnusdottir, O. T. Magnusson, L. B. Olafsdottir, S. Rognvaldsson, L. le Roux, G.
- 762 Sigmundsdottir, A. Sigurdsson, G. Sveinbjornsson, K. E. Sveinsdottir, M. Sveinsdottir, E.
- 763 A. Thorarensen, B. Thorbjornsson, M. Thordardottir, J. Saemundsdottir, S. H. Kristjansson,
- K. S. Josefsdottir, G. Masson, G. Georgsson, M. Kristjansson, A. Moller, R. Palsson, T.

It is made available under a CC-BY-NC-ND 4.0 International license .

765		Gudnason, U. Thorsteinsdottir, I. Jonsdottir, P. Sulem, K. Stefansson, Humoral Immune
766		Response to SARS-CoV-2 in Iceland. New England Journal of Medicine. 383, 1724–1734
767		(2020).
768	18.	A. S. Iyer, F. K. Jones, A. Nodoushani, M. Kelly, M. Becker, D. Slater, R. Mills, E. Teng,
769		M. Kamruzzaman, W. F. Garcia-Beltran, M. Astudillo, D. Yang, T. E. Miller, E. Oliver, S.
770		Fischinger, C. Atyeo, A. J. Iafrate, S. B. Calderwood, S. A. Lauer, J. Yu, Z. Li, J. Feldman,
771		B. M. Hauser, T. M. Caradonna, J. A. Branda, S. E. Turbett, R. C. LaRocque, G. Mellon, D.
772		H. Barouch, A. G. Schmidt, A. S. Azman, G. Alter, E. T. Ryan, J. B. Harris, R. C. Charles,
773		Persistence and decay of human antibody responses to the receptor binding domain of
774		SARS-CoV-2 spike protein in COVID-19 patients. Sci Immunol. 5, eabe0367 (2020).
775	19.	J. Prévost, R. Gasser, G. Beaudoin-Bussières, J. Richard, R. Duerr, A. Laumaea, S. P.
776		Anand, G. Goyette, M. Benlarbi, S. Ding, H. Medjahed, A. Lewin, J. Perreault, T.
777		Tremblay, G. Gendron-Lepage, N. Gauthier, M. Carrier, D. Marcoux, A. Piché, M. Lavoie,
778		A. Benoit, V. Loungnarath, G. Brochu, E. Haddad, H. D. Stacey, M. S. Miller, M.
779		Desforges, P. J. Talbot, G. T. G. Maule, M. Côté, C. Therrien, B. Serhir, R. Bazin, M.
780		Roger, A. Finzi, Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2
781		Spike. Cell Rep Med. 1, 100126 (2020).
782	20.	H. Hou, T. Wang, B. Zhang, Y. Luo, L. Mao, F. Wang, S. Wu, Z. Sun, Detection of IgM
783		and IgG antibodies in patients with coronavirus disease 2019. Clin Transl Immunology. 9,
784		e1136 (2020).
785	21.	B. Zhang, X. Zhou, C. Zhu, Y. Song, F. Feng, Y. Qiu, J. Feng, Q. Jia, Q. Song, B. Zhu, J.

786 Wang, Immune Phenotyping Based on the Neutrophil-to-Lymphocyte Ratio and IgG Level

It is made available under a CC-BY-NC-ND 4.0 International license .

- 787 Predicts Disease Severity and Outcome for Patients With COVID-19. Frontiers in
- 788 *Molecular Biosciences*. **7**, 157 (2020).
- 22. M. S. Suthar, M. G. Zimmerman, R. C. Kauffman, G. Mantus, S. L. Linderman, W. H.
- Hudson, A. Vanderheiden, L. Nyhoff, C. W. Davis, O. Adekunle, M. Affer, M. Sherman, S.
- 791 Reynolds, H. P. Verkerke, D. N. Alter, J. Guarner, J. Bryksin, M. C. Horwath, C. M.
- 792 Arthur, N. Saakadze, G. H. Smith, S. Edupuganti, E. M. Scherer, K. Hellmeister, A. Cheng,
- J. A. Morales, A. S. Neish, S. R. Stowell, F. Frank, E. Ortlund, E. J. Anderson, V. D.
- Menachery, N. Rouphael, A. K. Mehta, D. S. Stephens, R. Ahmed, J. D. Roback, J.
- 795 Wrammert, Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients.
- 796 *Cell Reports Medicine*. **1**, 100040 (2020).
- 797 23. P. J. M. Brouwer, T. G. Caniels, K. van der Straten, J. L. Snitselaar, Y. Aldon, S. Bangaru,
- J. L. Torres, N. M. A. Okba, M. Claireaux, G. Kerster, A. E. H. Bentlage, M. M. van
- Haaren, D. Guerra, J. A. Burger, E. E. Schermer, K. D. Verheul, N. van der Velde, A. van
- der Kooi, J. van Schooten, M. J. van Breemen, T. P. L. Bijl, K. Sliepen, A. Aartse, R.
- 801 Derking, I. Bontjer, N. A. Kootstra, W. J. Wiersinga, G. Vidarsson, B. L. Haagmans, A. B.
- 802 Ward, G. J. de Bree, R. W. Sanders, M. J. van Gils, Potent neutralizing antibodies from
- 803 COVID-19 patients define multiple targets of vulnerability. *Science*. **369**, 643–650 (2020).
- 804 24. T. F. Rogers, F. Zhao, D. Huang, N. Beutler, A. Burns, W. He, O. Limbo, C. Smith, G.
- 805 Song, J. Woehl, L. Yang, R. K. Abbott, S. Callaghan, E. Garcia, J. Hurtado, M. Parren, L.
- 806 Peng, S. Ramirez, J. Ricketts, M. J. Ricciardi, S. A. Rawlings, N. C. Wu, M. Yuan, D. M.
- 807 Smith, D. Nemazee, J. R. Teijaro, J. E. Voss, I. A. Wilson, R. Andrabi, B. Briney, E.
- 808 Landais, D. Sok, J. G. Jardine, D. R. Burton, Isolation of potent SARS-CoV-2 neutralizing

- antibodies and protection from disease in a small animal model. *Science*. 369, 956–963
 (2020).
- 811 25. A. Wajnberg, F. Amanat, A. Firpo, D. R. Altman, M. J. Bailey, M. Mansour, M. McMahon,
- 812 P. Meade, D. R. Mendu, K. Muellers, D. Stadlbauer, K. Stone, S. Strohmeier, V. Simon, J.
- 813 Aberg, D. L. Reich, F. Krammer, C. Cordon-Cardo, Robust neutralizing antibodies to
- 814 SARS-CoV-2 infection persist for months. *Science*. **370**, 1227–1230 (2020).
- 815 26. C. Feng, J. Shi, Q. Fan, Y. Wang, H. Huang, F. Chen, G. Tang, Y. Li, P. Li, J. Li, J. Cui, L.
- 816 Guo, S. Chen, M. Jiang, L. Feng, L. Chen, C. Lei, C. Ke, X. Deng, F. Hu, X. Tang, F. Li,
- 817 Protective humoral and cellular immune responses to SARS-CoV-2 persist up to 1 year
- 818 after recovery. *Nat Commun.* **12**, 4984 (2021).
- 819 27. G. Rijkers, J.-L. Murk, B. Wintermans, B. van Looy, M. van den Berge, J. Veenemans, J.
- 820 Stohr, C. Reusken, P. van der Pol, J. Reimerink, Differences in Antibody Kinetics and
- 821 Functionality Between Severe and Mild Severe Acute Respiratory Syndrome Coronavirus 2
- 822 Infections. J Infect Dis, jiaa463 (2020).
- 823 28. C. Rydyznski Moderbacher, S. I. Ramirez, J. M. Dan, A. Grifoni, K. M. Hastie, D.
- 824 Weiskopf, S. Belanger, R. K. Abbott, C. Kim, J. Choi, Y. Kato, E. G. Crotty, C. Kim, S. A.
- Rawlings, J. Mateus, L. P. V. Tse, A. Frazier, R. Baric, B. Peters, J. Greenbaum, E.
- 826 Ollmann Saphire, D. M. Smith, A. Sette, S. Crotty, Antigen-Specific Adaptive Immunity to
- 827 SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. *Cell*.
- 828 **183**, 996-1012.e19 (2020).
- 829 29. F. Tea, A. O. Stella, A. Aggarwal, D. R. Darley, D. Pilli, D. Vitale, V. Merheb, F. X. Z.
- 830 Lee, P. Cunningham, G. J. Walker, C. Fichter, D. A. Brown, W. D. Rawlinson, S. R. Isaacs,
- 831 V. Mathivanan, M. Hoffmann, S. Pöhlman, O. Mazigi, D. Christ, D. E. Dwyer, R. J.

It is made available under a CC-BY-NC-ND	0 4.0 International license .
--	-------------------------------

832		Rockett, V. Sintchenko, V. C. Hoad, D. O. Irving, G. J. Dore, I. B. Gosbell, A. D. Kelleher,
833		G. V. Matthews, F. Brilot, S. G. Turville, SARS-CoV-2 neutralizing antibodies: Longevity,
834		breadth, and evasion by emerging viral variants. PLOS Medicine. 18, e1003656 (2021).
835	30.	K. Röltgen, A. E. Powell, O. F. Wirz, B. A. Stevens, C. A. Hogan, J. Najeeb, M. Hunter, H.
836		Wang, M. K. Sahoo, C. Huang, F. Yamamoto, M. Manohar, J. Manalac, A. R. Otrelo-
837		Cardoso, T. D. Pham, A. Rustagi, A. J. Rogers, N. H. Shah, C. A. Blish, J. R. Cochran, T.
838		S. Jardetzky, J. L. Zehnder, T. T. Wang, B. Narasimhan, S. Gombar, R. Tibshirani, K. C.
839		Nadeau, P. S. Kim, B. A. Pinsky, S. D. Boyd, Defining the features and duration of
840		antibody responses to SARS-CoV-2 infection associated with disease severity and outcome.
841		Sci Immunol. 5, eabe0240 (2020).
842	31.	J. Zhang, H. Lin, B. Ye, M. Zhao, J. Zhan, S. Dong, Y. Guo, Y. Zhao, M. Li, S. Liu, H.
843		Zhang, W. Xiao, Y. Guo, C. Yue, D. Zhang, M. Yang, J. Zhang, C. Quan, W. Shi, X. Liu,
844		P. Liu, Y. Jiang, G. Wu, G. F. Gao, W. J. Liu, One-year sustained cellular and humoral
845		immunities of COVID-19 convalescents. Clin Infect Dis, ciab884 (2021).
846	32.	S. Glöckner, F. Hornung, M. Baier, S. Weis, M. W. Pletz, S. Deinhardt-Emmer, B. Löffler,
847		the CoNAN Study Group, Robust Neutralizing Antibody Levels Detected after Either
848		SARS-CoV-2 Vaccination or One Year after Infection. Viruses. 13, 2003 (2021).
849	33.	S. F. Lumley, D. O'Donnell, N. E. Stoesser, P. C. Matthews, A. Howarth, S. B. Hatch, B.
850		D. Marsden, S. Cox, T. James, F. Warren, L. J. Peck, T. G. Ritter, Z. de Toledo, L. Warren,
851		D. Axten, R. J. Cornall, E. Y. Jones, D. I. Stuart, G. Screaton, D. Ebner, S. Hoosdally, M.
852		Chand, D. W. Crook, AM. O'Donnell, C. P. Conlon, K. B. Pouwels, A. S. Walker, T. E.
853		A. Peto, S. Hopkins, T. M. Walker, K. Jeffery, D. W. Eyre, Antibody Status and Incidence

- of SARS-CoV-2 Infection in Health Care Workers. *New England Journal of Medicine*
- 855 (2020), doi:10.1056/NEJMoa2034545.
- 856 34. Z. Wang, F. Muecksch, D. Schaefer-Babajew, S. Finkin, C. Viant, C. Gaebler, H.-H.
- 857 Hoffmann, C. O. Barnes, M. Cipolla, V. Ramos, T. Y. Oliveira, A. Cho, F. Schmidt, J. Da
- 858 Silva, E. Bednarski, L. Aguado, J. Yee, M. Daga, M. Turroja, K. G. Millard, M. Jankovic,
- A. Gazumyan, Z. Zhao, C. M. Rice, P. D. Bieniasz, M. Caskey, T. Hatziioannou, M. C.
- 860 Nussenzweig, Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after
- 861 infection. *Nature*. **595**, 426–431 (2021).
- 862 35. L. Yao, G.-L. Wang, Y. Shen, Z.-Y. Wang, B.-D. Zhan, L.-J. Duan, B. Lu, C. Shi, Y.-M.
- 863 Gao, H.-H. Peng, G.-Q. Wang, D.-M. Wang, M.-D. Jiang, G.-P. Cao, M.-J. Ma, Persistence
- 864 of Antibody and Cellular Immune Responses in COVID-19 patients over Nine Months after
 865 Infection. *J Infect Dis*, jiab255 (2021).
- 36. J. S. Turner, W. Kim, E. Kalaidina, C. W. Goss, A. M. Rauseo, A. J. Schmitz, L. Hansen,
- 867 A. Haile, M. K. Klebert, I. Pusic, J. A. O'Halloran, R. M. Presti, A. H. Ellebedy, SARS-
- 868 CoV-2 infection induces long-lived bone marrow plasma cells in humans. *Nature*. **595**,
- 869 421–425 (2021).
- 870 37. K. Vanshylla, V. Di Cristanziano, F. Kleipass, F. Dewald, P. Schommers, L. Gieselmann,
- 871 H. Gruell, M. Schlotz, M. S. Ercanoglu, R. Stumpf, P. Mayer, M. Zehner, E. Heger, W.
- Johannis, C. Horn, I. Suárez, N. Jung, S. Salomon, K. A. Eberhardt, B. Gathof, G.
- 873 Fätkenheuer, N. Pfeifer, R. Eggeling, M. Augustin, C. Lehmann, F. Klein, Kinetics and
- 874 correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans. *Cell*
- 875 *Host & Microbe.* **29**, 917-929.e4 (2021).

It is made available under a CC-BY-NC-ND 4.0 International license .

- 876 38. C. Manisty, T. A. Treibel, M. Jensen, A. Semper, G. Joy, R. K. Gupta, T. Cutino-Moguel,
- 877 M. Andiapen, J. Jones, S. Taylor, A. Otter, C. Pade, J. Gibbons, J. Lee, J. Bacon, S.
- Thomas, C. Moon, M. Jones, D. Williams, J. Lambourne, M. Fontana, D. M. Altmann, R.
- 879 Boyton, M. Maini, A. McKnight, B. Chain, M. Noursadeghi, J. C. Moon, Time series
- analysis and mechanistic modelling of heterogeneity and sero-reversion in antibody
- responses to mild SARS-CoV-2 infection. *EBioMedicine*. **65** (2021),
- doi:10.1016/j.ebiom.2021.103259.
- 883 39. P. G. Choe, C. K. Kang, H. J. Suh, J. Jung, K.-H. Song, J. H. Bang, E. S. Kim, H. B. Kim,
- 884 S. W. Park, N. J. Kim, W. B. Park, M. Oh, Waning Antibody Responses in Asymptomatic
- and Symptomatic SARS-CoV-2 Infection. *Emerg Infect Dis.* 27, 327–329 (2021).
- 886 40. Q.-X. Long, X.-J. Tang, Q.-L. Shi, Q. Li, H.-J. Deng, J. Yuan, J.-L. Hu, W. Xu, Y. Zhang,
- 887 F.-J. Lv, K. Su, F. Zhang, J. Gong, B. Wu, X.-M. Liu, J.-J. Li, J.-F. Qiu, J. Chen, A.-L.
- 888 Huang, Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections.
- 889 *Nat Med.* **26**, 1200–1204 (2020).
- 41. Q. Lei, Y. Li, H. Hou, F. Wang, Z. Ouyang, Y. Zhang, D. Lai, J.-L. Banga Ndzouboukou,
- Z. Xu, B. Zhang, H. Chen, J. Xue, X. Lin, Y. Zheng, Z. Yao, X. Wang, C. Yu, H. Jiang, H.
- 892 Zhang, H. Qi, S. Guo, S. Huang, Z. Sun, S. Tao, X. Fan, Antibody dynamics to SARS-
- 893 CoV-2 in asymptomatic COVID-19 infections. *Allergy*. **76**, 551–561 (2021).
- 42. F. J. Ibarrondo, J. A. Fulcher, D. Goodman-Meza, J. Elliott, C. Hofmann, M. A. Hausner,
- 895 K. G. Ferbas, N. H. Tobin, G. M. Aldrovandi, O. O. Yang, Rapid Decay of Anti-SARS-
- 896 CoV-2 Antibodies in Persons with Mild Covid-19. N Engl J Med (2020),
- doi:10.1056/NEJMc2025179.

898	43.	S. Schwarzkopf, A. Krawczyk, D. Knop, H. Klump, A. Heinold, F. M. Heinemann, L.
899		Thümmler, C. Temme, M. Breyer, O. Witzke, U. Dittmer, V. Lenz, P. A. Horn, M.
900		Lindemann, Cellular Immunity in COVID-19 Convalescents with PCR-Confirmed
901		Infection but with Undetectable SARS-CoV-2-Specific IgG - Volume 27, Number 1-
902		January 2021 - Emerging Infectious Diseases journal - CDC, doi:10.3201/eid2701.203772.
903	44.	D. Weiskopf, K. S. Schmitz, M. P. Raadsen, A. Grifoni, N. M. A. Okba, H. Endeman, J. P.
904		C. van den Akker, R. Molenkamp, M. P. G. Koopmans, E. C. M. van Gorp, B. L.
905		Haagmans, R. L. de Swart, A. Sette, R. D. de Vries, Phenotype and kinetics of SARS-CoV-
906		2-specific T cells in COVID-19 patients with acute respiratory distress syndrome. Sci
907		<i>Immunol.</i> 5 , eabd2071 (2020).
908	45.	C. Fenwick, A. Croxatto, A. T. Coste, F. Pojer, C. André, C. Pellaton, A. Farina, J.
909		Campos, D. Hacker, K. Lau, BJ. Bosch, S. G. Nussle, M. Bochud, V. D'Acremont, D.
910		Trono, G. Greub, G. Pantaleo, Changes in SARS-CoV-2 Spike versus Nucleoprotein
911		Antibody Responses Impact the Estimates of Infections in Population-Based
912		Seroprevalence Studies. J. Virol. 95, e01828-20 (2021).
913	46.	C. Genolini, X. Alacoque, M. Sentenac, C. Arnaud, kml and kml3d: R Packages to Cluster
914		Longitudinal Data. Journal of Statistical Software. 65, 1–34 (2015).
915	47.	C. Genolini, J. B. Pingault, T. Driss, S. Côté, R. E. Tremblay, F. Vitaro, C. Arnaud, B.
916		Falissard, KmL3D: A non-parametric algorithm for clustering joint trajectories. Computer
917		Methods and Programs in Biomedicine. 109, 104–111 (2013).
918	48.	T. Takahashi, M. K. Ellingson, P. Wong, B. Israelow, C. Lucas, J. Klein, J. Silva, T. Mao,
919		J. E. Oh, M. Tokuyama, P. Lu, A. Venkataraman, A. Park, F. Liu, A. Meir, J. Sun, E. Y.
920		Wang, A. Casanovas-Massana, A. L. Wyllie, C. B. F. Vogels, R. Earnest, S. Lapidus, I. M.

medRxiv preprint doi: https://doi.org/10.1101/2021.12.15.21267776; this version posted December 16, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

921 Ot	t, A. J. Moore,	A. Shaw.	J. B. Fournier	. C. D. Odio	. S. Farhadian.	C. D. Cruz.	N. D.

- 922 Grubaugh, W. L. Schulz, A. M. Ring, A. I. Ko, S. B. Omer, A. Iwasaki, Sex differences in
- 923 immune responses that underlie COVID-19 disease outcomes. *Nature*. **588**, 315–320
- 924 (2020).
- 925 49. J. Wei, P. C. Matthews, N. Stoesser, T. Maddox, L. Lorenzi, R. Studley, J. I. Bell, J. N.
- 926 Newton, J. Farrar, I. Diamond, E. Rourke, A. Howarth, B. D. Marsden, S. Hoosdally, E. Y.
- 927 Jones, D. I. Stuart, D. W. Crook, T. E. A. Peto, K. B. Pouwels, A. S. Walker, D. W. Eyre,
- 928 Anti-spike antibody response to natural SARS-CoV-2 infection in the general population.
- 929 *Nat Commun.* **12**, 6250 (2021).
- 930 50. L. Piccoli, Y.-J. Park, M. A. Tortorici, N. Czudnochowski, A. C. Walls, M. Beltramello, C.
- 931 Silacci-Fregni, D. Pinto, L. E. Rosen, J. E. Bowen, O. J. Acton, S. Jaconi, B. Guarino, A.
- 932 Minola, F. Zatta, N. Sprugasci, J. Bassi, A. Peter, A. De Marco, J. C. Nix, F. Mele, S. Jovic,
- B. F. Rodriguez, S. V. Gupta, F. Jin, G. Piumatti, G. Lo Presti, A. F. Pellanda, M.
- 934 Biggiogero, M. Tarkowski, M. S. Pizzuto, E. Cameroni, C. Havenar-Daughton, M.
- 935 Smithey, D. Hong, V. Lepori, E. Albanese, A. Ceschi, E. Bernasconi, L. Elzi, P. Ferrari, C.
- 936 Garzoni, A. Riva, G. Snell, F. Sallusto, K. Fink, H. W. Virgin, A. Lanzavecchia, D. Corti,
- 937 D. Veesler, Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike
- 938 Receptor-Binding Domain by Structure-Guided High-Resolution Serology. *Cell.* 183, 1024939 1042.e21 (2020).
- 940 51. K. W. Cohen, S. L. Linderman, Z. Moodie, J. Czartoski, L. Lai, G. Mantus, C. Norwood, L.
- 941 E. Nyhoff, V. V. Edara, K. Floyd, S. C. D. Rosa, H. Ahmed, R. Whaley, S. N. Patel, B.
- 942 Prigmore, M. P. Lemos, C. W. Davis, S. Furth, J. O'Keefe, M. P. Gharpure, S. Gunisetty,
- 943 K. A. Stephens, R. Antia, V. I. Zarnitsyna, D. S. Stephens, S. Edupuganti, N. Rouphael, E.

- J. Anderson, A. K. Mehta, J. Wrammert, M. S. Suthar, R. Ahmed, M. J. McElrath, in press,
 doi:10.1101/2021.04.19.21255739.
- 946 52. W. S. Lee, K. J. Selva, S. K. Davis, B. D. Wines, A. Reynaldi, R. Esterbauer, H. G. Kelly,
- E. R. Haycroft, H.-X. Tan, J. A. Juno, A. K. Wheatley, P. M. Hogarth, D. Cromer, M. P.
- Davenport, A. W. Chung, S. J. Kent, Decay of Fc-dependent antibody functions after mild
 to moderate COVID-19. *Cell Reports Medicine*. 2, 100296 (2021).
- 950 53. L. Premkumar, B. Segovia-Chumbez, R. Jadi, D. R. Martinez, R. Raut, A. Markmann, C.
- 951 Cornaby, L. Bartelt, S. Weiss, Y. Park, C. E. Edwards, E. Weimer, E. M. Scherer, N.
- 952 Rouphael, S. Edupuganti, D. Weiskopf, L. V. Tse, Y. J. Hou, D. Margolis, A. Sette, M. H.
- 953 Collins, J. Schmitz, R. S. Baric, A. M. de Silva, The receptor binding domain of the viral
- 954 spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-
- 955 2 patients. *Sci Immunol.* **5**, eabc8413 (2020).
- 956 54. J. H. Jung, M.-S. Rha, M. Sa, H. K. Choi, J. H. Jeon, H. Seok, D. W. Park, S.-H. Park, H.
- 957 W. Jeong, W. S. Choi, E.-C. Shin, SARS-CoV-2-specific T cell memory is sustained in
- 958 COVID-19 convalescent patients for 10 months with successful development of stem cell-
- 959 like memory T cells. *Nat Commun.* **12**, 4043 (2021).
- 960 55. J. Neidleman, X. Luo, J. Frouard, G. Xie, G. Gill, E. S. Stein, M. McGregor, T. Ma, A. F.
- 961 George, A. Kosters, W. C. Greene, J. Vasquez, E. Ghosn, S. Lee, N. R. Roan, SARS-CoV-
- 962 2-Specific T Cells Exhibit Phenotypic Features of Helper Function, Lack of Terminal
- 963 Differentiation, and High Proliferation Potential. *Cell Reports Medicine*. **1**, 100081 (2020).
- 964 56. H. Hou, Y. Zhang, G. Tang, Y. Luo, W. Liu, C. Cheng, Y. Jiang, Z. Xiong, S. Wu, Z. Sun,
- 965 S. Xu, X. Fan, F. Wang, Immunologic memory to SARS-CoV-2 in convalescent COVID-

966	19 patients at 1 year postinfection. Journal of Allergy and Clinical Immunology. 0 (2021),
967	doi:10.1016/j.jaci.2021.09.008.

- 968 57. Y. Peng, A. J. Mentzer, G. Liu, X. Yao, Z. Yin, D. Dong, W. Dejnirattisai, T. Rostron, P.
- 969 Supasa, C. Liu, C. López-Camacho, J. Slon-Campos, Y. Zhao, D. I. Stuart, G. C. Paesen, J.
- 970 M. Grimes, A. A. Antson, O. W. Bayfield, D. E. D. P. Hawkins, D.-S. Ker, B. Wang, L.
- 971 Turtle, K. Subramaniam, P. Thomson, P. Zhang, C. Dold, J. Ratcliff, P. Simmonds, T. de
- 972 Silva, P. Sopp, D. Wellington, U. Rajapaksa, Y.-L. Chen, M. Salio, G. Napolitani, W. Paes,
- 973 P. Borrow, B. M. Kessler, J. W. Fry, N. F. Schwabe, M. G. Semple, J. K. Baillie, S. C.
- 974 Moore, P. J. M. Openshaw, M. A. Ansari, S. Dunachie, E. Barnes, J. Frater, G. Kerr, P.
- 975 Goulder, T. Lockett, R. Levin, Y. Zhang, R. Jing, L.-P. Ho, R. J. Cornall, C. P. Conlon, P.
- 976 Klenerman, G. R. Screaton, J. Mongkolsapaya, A. McMichael, J. C. Knight, G. Ogg, T.
- 977 Dong, Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK
- 978 convalescent individuals following COVID-19. *Nat Immunol.* **21**, 1336–1345 (2020).
- 979 58. ISRCTN14990068: Zurich Coronavirus Cohort: an observational study to determine long-
- 980 term clinical outcomes and immune responses after coronavirus infection (COVID-19),
- 981 assess the influence of virus genetics, and examine the spread of the coronavirus in the
- 982 population of the Canton of Zurich, Switzerland. ISRCTN Registry (2020),
- 983 doi:10.1186/ISRCTN14990068.
- 984 59. A. L. Whitcombe, R. McGregor, A. Craigie, A. James, R. Charlewood, N. Lorenz, J. M.
- 985 Dickson, C. R. Sheen, B. Koch, S. Fox-Lewis, G. McAuliffe, S. A. Roberts, S. C. Morpeth,
- 986 S. Taylor, R. H. Webb, S. Jack, A. Upton, J. E. Ussher, N. J. Moreland, Comprehensive
- 987 analysis of SARS-CoV-2 antibody dynamics in New Zealand. *Clin Transl Immunology*. 10,
- 988 e1261 (2021).

medRxiv preprint doi: https://doi.org/10.1101/2021.12.15.21267776; this version posted December 16, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

989	60.	M. Poehler, L. Gibson, A. Lustig, N. J. Moreland, R. McGregor, A. James, in pres	s,
990		doi:10.1101/2021.06.13.21258857.	

- 61. S. M. Kaech, W. Cui, Transcriptional control of effector and memory CD8+ T cell
 differentiation. *Nat Rev Immunol.* 12, 749–761 (2012).
- 993 62. R Core Team, R: A language and environment for statistical computing. R Foundation for
- 994 Statistical Computing. *Vienna, Austria* (2021), (available at https://www. R-project.org/).

- Acknowledgments: The authors would like to thank the study administration team and the study
 participants for their dedicated contribution to this research project.
- 998 **Funding:** This study is part of Corona Immunitas research network, coordinated by the Swiss
- 999 School of Public Health (SSPH+), and funded by fundraising of SSPH+ that includes
- 1000 funds of the Swiss Federal Office of Public Health and private funders (ethical guidelines
- 1001 for funding stated by SSPH+ will be respected), by funds of the Cantons of Switzerland
- 1002 (Vaud, Zurich, and Basel) and by institutional funds of the Universities. Additional
- 1003 funding, specific to this study was received from the Department of Health of the Canton
- 1004 of Zurich, the University of Zurich Foundation, and the Swiss Federal Office of Public
- 1005 Health. The funding bodies had no influence on the study design or the conduct, analysis,
- 1006 or interpretation of the study findings. TB received funding from the European Union's
- 1007 Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie
- 1008 grant agreement No 801076, through the SSPH+ Global PhD Fellowship Programme in
- 1009 Public Health Sciences (GlobalP3HS) of the SSPH+. HA received an Swiss National
- 1010 Science Foundation (SNSF) Early Postdoc.Mobility Fellowship.

It is made available under a CC-BY-NC-ND 4.0 International license .

1011

1012 Author contributions:

- 1013 Conceptualization: DM, KDZ, TB, CM, MAP, JSF
- 1014 Methodology: DM, KDZ, TB, NC, CP, MP, CF, GP, CM, MAP, JSF
- 1015 Investigation: DM, KDZ, TB, NC, CP, MP, CF, GP, CRK
- 1016 Visualization: DM, KDZ, TB, NC
- 1017 Funding acquisition: MAP, JSF
- 1018 Project administration: DM, TB, HEA, AD, MAP
- 1019 Supervision: CM, MAP, JSF
- 1020 Writing original draft: DM, KDZ, TB
- 1021 Writing review & editing: DM, KDZ, TB, NC, DLC, HEA, AD, CP, MP, CF, GP, CRK,
- 1022 CM, MAP, JSF
- 1023
- 1024 **Competing interests:** The authors declare that they have no competing interests.

1025 Data and materials availability: All data are available in the main text or the supplementary

1026 materials.

1027

It is made available under a CC-BY-NC-ND 4.0 International license .

1029 Figures:





Fig. 1. Study design and population characteristics. (A) Figure showing the overall study
 design, assessments conducted on and baseline clinical characteristics of all enrolled
 participants (n=431). (B) Figure showing the assessments conducted on and clinical
 characteristics of a randomly selected subsample of participants covering the full range of
 the infected population (n=64).






1037 Fig. 2. Anti-SARS-CoV-2 S-IgA, S-IgG, N-IgG-specific antibody responses over time. (A) 1038 Scatter and distributional plots demonstrating the measured mean fluorescence intensity 1039 (MFI) ratios for anti-S-IgA antibodies in the overall study population (n=431), overall 1040 and stratified by age groups and sex. MFI: mean fluorescence intensity, W2: two weeks, 1041 M1: one month, M3: three months, M6: six months after diagnosis. (B) Scatter and 1042 distributional plots of measured MFI ratios for anti-S-IgG antibodies in the overall study 1043 population (n=431), overall and stratified by age groups and sex. (C) Scatter and 1044 distributional plots of measured MFI ratios for anti-S-IgG antibodies within the 1045 subsample of individuals undergoing detailed testing (n=64), overall and stratified by age 1046 groups and sex. (D) Anti-S-IgA antibody decay estimation based on mixed linear

It is made available under a CC-BY-NC-ND 4.0 International license .


1047regression model. Adj. t_{1/2}: half-life based on model adjusted for time from diagnosis to1048maximum MFI ratio, age group, sex and symptom count, using a random intercept for1049each individual in the study. (E) Anti-S-IgG antibody decay estimation based on mixed1050linear regression mode. (F) Anti-N-IgG antibody decay estimation within the subsample,1051based on mixed linear regression model.




It is made available under a CC-BY-NC-ND 4.0 International license .

1056	indicated timepoints post-diagnosis. Spec. TC: specific T cells, W2: two weeks, M1: one
1057	month, M3: three months, M6: six months after diagnosis. (C) Representative flow
1058	cytometry plots depicting AIM ⁺ (CD134 ⁺ CD137 ⁺) CD4 ⁺ (left) and (CD69 ⁺ CD137 ⁺)
1059	CD8 ⁺ (right) populations in unstimulated (top) or pooled SARS-CoV-2 peptide-
1060	stimulated (bottom) PBMCs. (D) AIM ⁺ cells as a fraction of CD4 ⁺ or CD8 ⁺ T cells at
1061	indicated timepoints post-diagnosis. Horizontal lines represent mean at timepoint. (E)
1062	Percentage of CD4 ⁺ or CD8 ⁺ AIM ⁺ T cells with TCM (CD45RA ⁻ CCR7 ⁺), TEM
1063	(CD45RA ⁻ CCR7 ⁻) or TEMRA (CD45RA ⁺ CCR7 ⁻) phenotypes by day post-diagnosis.

1064





demonstrating the correlation between anti-S-IgA and IgG and anti-N-IgG antibody
subtypes and M-, N-, S1- and S2-specific T cells at the different timepoints. Numbers in
individual cells correspond to the Spearman correlation coefficient. W2: two weeks, M1:
one month, M3: three months, M6: six months after diagnosis. (B) Panel demonstrating

It is made available under a CC-BY-NC-ND 4.0 International license .

1070

the proportion of participants with concordant and discordant results between anti-S-IgA,

1071 anti-S-IgG and anti-N-IgG antibody subtypes and overall T cell positivity over time.






Fig. 5. Clustering of antibody and T cell response trajectories. (A) Panel demonstrating the
 mean MFI ratios of anti-S-IgA, anti-S-IgG and anti-N-IgG antibodies and mean M-, N-,
 S1-, and S-specific T cells/1e6 PBMCs in each of the five clusters over time. Displayed

1076	data was natural logarithm-transformed and normalized. W2: two weeks, M1: one month,
1077	M3: three months, M6: six months after diagnosis. (B) Heatmap showing the MFI ratios
1078	of anti-S-IgA, anti-S-IgG and anti-N antibodies and M-, N-, S1-, and S-specific T
1079	cells/1e6 PBMCs for all participants belonging to the identified clusters 1 to 5. Gray
1080	color indicates missing values. (C) Dot plots of anti-S-IgG MFI ratio, N-specific T
1081	cells/1e6 PBMCs, S-specific T cells/1e6 PBMCs and frequency of AIM^+ of $CD4^+$ T cells
1082	in the five clusters over time. Horizontal lines represent mean at timepoint. (D) Bar plot
1083	showing the proportion of participants according belonging to different age groups (18-
1084	39 years, 40-64 years, ≥65 years), sex (male and female), smoking status (non-smoker,
1085	ex-smoker, smoker), number of symptoms reported (asymptomatic, 1-5 symptoms, ≥ 6
1086	symptoms), and hospitalization status (non-hospitalized, hospitalized) during acute
1087	infection. Asymp.: asymptomatic, symp.: symptoms, hosp.: hospitalized.
1088	

It is made available under a CC-BY-NC-ND 4.0 International license .

1089





1099	adjustment as for panel A. (C) Forest plot showing results from adjusted mixed linear
1100	regression analyses evaluating the associations of anti-N-IgG MFI ratios with
1101	demographic and clinical factors in the subsample (n=64). Model adjustment as for panel
1102	A. (D) Forest plot demonstrating results from adjusted mixed linear regression analyses
1103	evaluating the associations of overall T cell counts per 1e6 PBMCs with demographic
1104	and clinical factors in the subsample (n=64). Model adjustment as for panel A.